PTEN and neoplasm: IHC for PTEN was performed on archival tumor samples and PTEN expression levels were compared with the treatment activity based on pre-clinical evidence of altered homologous recombination displayed by tumors without PTEN expression [51,52] and on the predictive role of PTEN loss for PARP inhibitors in endometrial cancers [53,54].